News for February 2018

News Archive

The Current issue of “The view from here” is concerned with Regulatory aspects of Drug Discovery. The Current issue of “The view from here” is concerned with Regulatory aspects of Drug Discovery.

The topic of this month’s newsletter from Drug Discovery Today is “Regulatory aspects of Drug Discovery”.

TC Biopharm and the NIPRO Corporation Announce Strategic Programme Co-Developing a Novel Gamma-Delta Car-T Product to Treat Cancer TC Biopharm and the NIPRO Corporation Announce Strategic Programme Co-Developing a Novel Gamma-Delta Car-T Product to Treat Cancer

Scottish Enterprise will contribute £2.7m via a ‘seek and solve’ grant to fund pre-clinical activities

Musical molecules and the battle for biological supremacy

The battle for supremacy between bacteria and antibiotics normally goes unseen, either behind closed doors in the laboratory or concealed deep within the human body. But now that complex contest is being translated into music thanks to a performance in which the worlds of art and science will combine to striking effect.

Elsevier Welcomes Six Biotech and Pharma Start-ups to The Hive, Supporting the Most Cutting-edge Research in Industry Elsevier Welcomes Six Biotech and Pharma Start-ups to The Hive, Supporting the Most Cutting-edge Research in Industry

Start-ups working on a range of technologies and discoveries - from AI to immunotherapy - receive complimentary access to Elsevier's information solutions to accelerate innovation

New project to transform biologics manufacture New project to transform biologics manufacture

The Centre for Process Innovation (CPI), the UK’s technology innovation provider for process manufacturing, today announced that it is in the final stages of a BBSRC-funded collaboration project with the University of Edinburgh’s Roslin Institute, to transform the way in which valuable proteins are manufactured for research, veterinary and human health. The project, hosted at CPI’s state-of-the-art National Biologics Manufacturing Centre, aims to develop commercially viable and scalable methods to produce biologics in transgenic animals, which will enable the production of cost-efficient, highly pure, biologically active therapeutic proteins.